Recent Research in LNCaP Cells Inhibition of BCL-2 by Antisense Oligonucleotides Results in Compensatory Changes Involving Apoptosis,Transcription and Immunoregulation

Science Press Release Distribution Services

Recent Research in LNCaP Cells Inhibition of BCL-2 by Antisense Oligonucleotides Results in Compensatory Changes Involving Apoptosis,Transcription and Immunoregulation

September 2, 2020 BIOLOGY 0

Antisense oligonucleotides (oligos) have been evaluated for treating prostate cancer in both in vivo

and in vitro models. This study evaluates the growth inhibition of in vitro propagating LNCaP cells

employing mono- and bi-specific oligos directed against BCL-2 and employing RT-PCR, the

expression of five apoptosis regulatory proteins (BCL-2, bax, caspase-3, clusterin, AKT-1), a tumor

associated transcription factor (MED-12) and an immune blockade associated regulatory marker (PDL1)

were evaluated. LNCaP prostate tumor cells were incubated in the presence of oligos specifically

directed against BCL-2 (entering the cells through a form of nanodelivery) and compared to lipofectin

containing controls. Significant, but comparable, growth inhibition was produced by both mono- and

bi-specific forms. Employing RT-PCR to determine BCL-2 expression, we found that the greatest

amount of mRNA suppression approached 100% for each type of oligo: Mono-specific MR4 (directed

only against BCL-2), 100%, and bispecifics MR24 and MR42, 86% and 100% respectively. The

objective of these experiments was to determine a compensatory response by cells to (again) evade

apoptosis in the presence of BCL-2 suppression. Levels of mRNA encoding non-targeted bax,

caspase-3, clusterin and AKT-1 were initially evaluated, while additional experiments sought to

identify additional mechanisms of tumor adaptability and resistance. Suppression of the apoptosis

inhibitor (BCL-2) in LNCaP cells did not alter either bax or clusterin expression. However, nontargeted

caspase-3 (an apoptosis promoter) was suppressed and non-targeted AKT-1 (an apoptosis

inhibitor) was enhanced. This suggests that tumor variants can resist apoptosis through the altered

expression of non-targeted regulators of apoptosis. Additional experiments identified other

mechanisms of compensation involving transcription and immune regulation suggesting further

studies are needed.

 

Author (s) Details

Marvin Rubenstein

Independent Researcher, 1070 Cobblestone Ct., Northbrook, IL 60062, USA.

View Book :- https://bp.bookpi.org/index.php/bpi/catalog/book/239

 

 

Leave a Reply

Your email address will not be published. Required fields are marked *